Multiparametric Analysis of Oncology Drug Screening with Aqueous Two-Phase Tumor Spheroids

Molecular Pharmaceutics

Volumn 13, Issue 11, 2016, Pages 3724-3735

  Thakuri, Pradip Shahi ^a   Ham, Stephanie L ^a   Luker, Gary D ^b   Tavana, Hossein ^a  

^a University of Akron   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

high throughput drug screening; multiparametric analysis; polymeric aqueous two phase system; robotic; target validation; tumor spheroids

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTINEOPLASTIC AGENT; CISPLATIN; CRIZOTINIB; DACTOLISIB; DOXORUBICIN; FLUOROURACIL; GANDOTINIB; GSK 1059615; HYALURONAN RESVERATROL; KI 67 ANTIGEN; KX2 391; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; OXALIPLATIN; PACLITAXEL; PANOBINOSTAT; PICTILISIB; PONATINIB; RIBOCICLIB; SELUMETINIB; SEPANTRONIUM BROMIDE; STAUROSPORINE; TANESPIMYCIN; TIRAPAZAMINE; TRAMETINIB; UNCLASSIFIED DRUG; VER 155008;

AQUEOUS TWO PHASE MICROTECHNOLOGY; ARTICLE; CANCER CELL; CELL DENSITY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; EXTRACELLULAR MATRIX; HIGH THROUGHPUT SCREENING; HT 29 CELL LINE; HUMAN; HUMAN CELL; IC50; MICROTECHNOLOGY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TUMOR MODEL; TUMOR SPHEROID; ANIMAL; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; MULTICELLULAR SPHEROID; PRECLINICAL STUDY; PROCEDURES; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; SPHEROIDS, CELLULAR;

EID: 84994517581     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.6b00527     Document Type: Article

References (59)

1. Eagle, H.; Foley, G. E. Cytotoxicity in human cell cultures as a primary screen for the detection of anti-tumor agents Cancer Res. 1958, 18 (9) 1017-1025
2. Smalley, K. S. M.; Lioni, M.; Herlyn, M. Life isn't flat: taking cancer biology to the next dimension In Vitro Cell Dev Biol. Anim. 2006, 42 (8-9) 242-247 10.1290/0604027.1
3. Waring, M. J.; Arrowsmith, J.; Leach, A. R.; Leeson, P. D.; Mandrell, S.; Owen, R. M.; Pairaudeau, G.; Pennie, W. D.; Pickett, S. D.; Wang, J.; Wallace, O.; Weir, A. An analysis of the attrition of drug candidates from four major pharmaceutical companies Nat. Rev. Drug Discovery 2015, 14 (7) 475-486 10.1038/nrd4609
4. Zambrowicz, B. P.; Sands, A. T. Knockouts model the 100 best-selling drugs - will they model the next 100? Nat. Rev. Drug Discovery 2003, 2 (1) 38-51 10.1038/nrd987
5. Hutchinson, L.; Kirk, R. High drug attrition rates - where are we going wrong? Nat. Rev. Clin. Oncol. 2011, 8 (4) 189-190 10.1038/nrclinonc.2011.34
6. Hait, W. N. Anticancer drug development: the grand challenges Nat. Rev. Drug Discovery 2010, 9 (4) 253-254 10.1038/nrd3144
7. Pampaloni, F.; Reynaud, E. G.; Stelzer, E. H. K. The third dimension bridges the gap between cell culture and live tissue Nat. Rev. Mol. Cell Biol. 2007, 8 (10) 839-845 10.1038/nrm2236
8. Park, M. H.; Song, B.; Hong, S.; Kim, S. H.; Lee, K. Biomimetic 3D clusters using human adipose derived mesenchymal stem cells and breast cancer cells: A study on migration and invasion of breast cancer cells Mol. Pharmaceutics 2016, 13 (7) 2204-13 10.1021/acs.molpharmaceut.5b00953
9. Tunggal, J. K.; Cowan, D. S.; Shaikh, H.; Tannock, I. F. Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors Clin. Cancer Res. 1999, 5 (6) 1583-1586
10. Xu, X.; Farach-Carson, M. C.; Jia, X. Three-dimensional in vitro tumor models for cancer research and drug evaluation Biotechnol. Adv. 2014, 32 (7) 1256-1268 10.1016/j.biotechadv.2014.07.009
11. Lee, S.-H.; Hong, J. H.; Park, H. K.; Park, J. S.; Kim, B. K.; Lee, J. Y.; Jeong, J. Y.; Yoon, G. S.; Inoue, M.; Choi, G. S.; Lee, I. K. Colorectal cancer-derived tumor spheroids retain the characteristics of original tumors Cancer Lett. 2015, 367 (1) 34-42 10.1016/j.canlet.2015.06.024
12. Eetezadi, S.; De Souza, R.; Vythilingam, M.; Lessa Cataldi, R.; Allen, C. Effects of doxorubicin delivery systems and mild hyperthermia on tissue penetration in 3D cell culture models of ovarian cancer residual disease Mol. Pharmaceutics 2015, 12 (11) 3973-3985 10.1021/acs.molpharmaceut.5b00426
13. Flach, E. H.; Rebecca, V. W.; Herlyn, M.; Smalley, K. S. M.; Anderson, A. R. A. Fibroblasts contribute to melanoma tumor growth and drug resistance Mol. Pharmaceutics 2011, 8 (6) 2039-2049 10.1021/mp200421k
14. Kenny, P. A.; Lee, G. Y.; Myers, C. A.; Neve, R. M.; Semeiks, J. R.; Spellman, P. T.; Lorenz, K.; Lee, E. H.; Barcellos-Hoff, M. H.; Petersen, O. W.; Gray, J. W.; Bissell, M. J. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression Mol. Oncol. 2007, 1 (1) 84-96 10.1016/j.molonc.2007.02.004
15. Fong, E. L. S.; Martinez, M.; Yang, J.; Mikos, A. G.; Navone, N. M.; Harrington, D. A.; Farach-Carson, M. C. Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening Mol. Pharmaceutics 2014, 11 (7) 2040-2050 10.1021/mp500085p
16. Ham, S. L.; Joshi, R.; Thakuri, P. S.; Tavana, H. Liquid-based three-dimensional tumor models for cancer research and drug discovery Exp. Biol. Med. 2016, 241 (9) 939-54 10.1177/1535370216643772
17. Tavana, H.; Jovic, A.; Mosadegh, B.; Lee, Q. Y.; Liu, X.; Luker, K. E.; Luker, G. D.; Weiss, S. J.; Takayama, S. Nanolitre liquid patterning in aqueous environments for spatially defined reagent delivery to mammalian cells Nat. Mater. 2009, 8 (9) 736-741 10.1038/nmat2515
18. Ham, S. L.; Atefi, E.; Fyffe, D.; Tavana, H. Robotic production of cancer cell spheroids with an aqueous two-phase system for drug testing J. Visualized Exp. 2015, 98) 52754 10.3791/52754
19. Atefi, E.; Joshi, R.; Mann, J. A.; Tavana, H. Interfacial tension effect on cell partition in aqueous two-phase systems ACS Appl. Mater. Interfaces 2015, 7 (38) 21305-21314 10.1021/acsami.5b05757
20. Atefi, E.; Mann, J. A.; Tavana, H. Ultralow interfacial tensions of aqueous two-phase systems measured using drop shape Langmuir 2014, 30 (32) 9691-9699 10.1021/la500930x
21. Lemmo, S.; Atefi, E.; Luker, G. D.; Tavana, H. Optimization of aqueous biphasic tumor spheroid microtechnology for anti-cancer drug testing in 3D culture Cell. Mol. Bioeng. 2014, 7 (3) 344-354 10.1007/s12195-014-0349-4
22. Da Violante, G.; Zerrouk, N.; Richard, I.; Provot, G.; Chaumeil, J. C.; Arnaud, P. Evaluation of the cytotoxicity effect of dimethyl sulfoxide (DMSO) on Caco2/TC7 colon tumor cell cultures Biol. Pharm. Bull. 2002, 25 (12) 1600-1603 10.1248/bpb.25.1600
23. Walenta, S.; Doetsch, J.; Mueller-Klieser, W.; Kunz-Schughart, L. A. Metabolic imaging in multicellular spheroids of oncogene-transfected fibroblasts J. Histochem. Cytochem. 2000, 48 (4) 509-522 10.1177/002215540004800409
24. Ingram, M.; Techy, G. B.; Saroufeem, R.; Yazan, O.; Narayan, K. S.; Goodwin, T. J.; Spaulding, G. F. Three-dimensional growth patterns of various human tumor cell lines in simulated microgravity of a NASA bioreactor In Vitro Cell. Dev. Biol.: Anim. 1997, 33 (6) 459-466 10.1007/s11626-997-0064-8
25. Kelm, J. M.; Timmins, N. E.; Brown, C. J.; Fussenegger, M.; Nielsen, L. K. Method for generation of homogeneous multicellular tumor spheroids applicable to a wide variety of cell types Biotechnol. Bioeng. 2003, 83 (2) 173-180 10.1002/bit.10655
26. Hsiao, A. Y.; Tung, Y.-C.; Kuo, C.-H.; Mosadegh, B.; Bedenis, R.; Pienta, K. J.; Takayama, S. Micro-ring structures stabilize microdroplets to enable long term spheroid culture in 384 hanging drop array plates Biomed. Microdevices 2012, 14 (2) 313-323 10.1007/s10544-011-9608-5
27. Lee, K.; Nam, K.; Oh, S.; Lim, J.; Kim, Y. P.; Lee, J. W.; Yu, J. H.; Ahn, S. H.; Kim, S. B.; Noh, D. Y.; Lee, T.; Shin, I. Extracellular matrix protein 1 regulates cell proliferation and trastuzumab resistance through activation of epidermal growth factor signaling Breast Cancer Res. 2014, 16 (6) 479 10.1186/s13058-014-0479-6
28. Gérard, C.; Goldbeter, A. The balance between cell cycle arrest and cell proliferation: control by the extracellular matrix and by contact inhibition Interface Focus 2014, 4 (3) 20130075 10.1098/rsfs.2013.0075
29. Ulrich, T. A.; de Juan Pardo, E. M.; Kumar, S. The mechanical rigidity of the extracellular matrix regulates the structure, motility, and proliferation of glioma cells Cancer Res. 2009, 69 (10) 4167-4174 10.1158/0008-5472.CAN-08-4859
30. Venning, F. A.; Wullkopf, L.; Erler, J. T.; Targeting, E. C. M. Disrupts Cancer Progression Front. Oncol. 2015, 5, 224 10.3389/fonc.2015.00224
31. Atefi, E.; Lemmo, S.; Fyffe, D.; Luker, G. D.; Tavana, H. High throughput, polymeric aqueous two-phase printing of tumor spheroids Adv. Funct. Mater. 2014, 24 (41) 6509-6515 10.1002/adfm.201401302
32. Fang, J. Y.; Richardson, B. C. The MAPK signalling pathways and colorectal cancer Lancet Oncol. 2005, 6 (5) 322-327 10.1016/S1470-2045(05)70168-6
33. Yeh, J. J.; Routh, E. D.; Rubinas, T.; Peacock, J.; Martin, T. D.; Shen, X. J.; Sandler, R. S.; Kim, H. J.; Keku, T. O.; Der, C. J. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer Mol. Cancer Ther. 2009, 8 (4) 834-843 10.1158/1535-7163.MCT-08-0972
34. Knobbe, C. B.; Merlo, A.; Reifenberger, G. Pten signaling in gliomas Neuro Oncol. 2002, 4 (3) 196-211 10.1215/S1522851702000029
35. Klingler-Hoffmann, M.; Bukczynska, P.; Tiganis, T. Inhibition of phosphatidylinositol 3-kinase signaling negates the growth advantage imparted by a mutant epidermal growth factor receptor on human glioblastoma cells Int. J. Cancer 2003, 105 (3) 331-339 10.1002/ijc.11085
36. Clark, M. J.; Homer, N.; O'Connor, B. D.; Chen, Z.; Eskin, A.; Lee, H.; Merriman, B.; Nelson, S. F. U87MG decoded: the genomic sequence of a cytogenetically aberrant human cancer cell line PLoS Genet. 2010, 6 (1) e1000832 10.1371/journal.pgen.1000832
37. Lawrence, R. T.; Perez, E. M.; Hernández, D.; Chris, P. M.; Miller, C. P.; Haas, K. M.; Irie, H. Y.; Lee, Su-In.; Blau, C. A.; Villen, J. The proteomic landscape of triple-negative breast cancer Cell Rep. 2015, 11 (4) 630-644 10.1016/j.celrep.2015.03.050
38. Walerych, D.; Napoli, M.; Collavin, L.; Del Sal, G. The rebel angel: mutant p53 as the driving oncogene in breast cancer Carcinogenesis 2012, 33 (11) 2007-2017 10.1093/carcin/bgs232
39. Yuen, H.-F.; Abramczyk, O.; Montgomery, G.; Chan, K. K.; Huang, Y. H.; Sasazuki, T.; Shirasawa, S.; Gopesh, S.; Chan, K. W.; Fennell, D.; Janne, P.; El-Tanani, M.; Murray, J. T. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells Biosci. Rep. 2012, 32 (4) 413-422 10.1042/BSR20120050
40. VanKlompenberg, M. K.; Bedalov, C. O.; Soto, K. F.; Prosperi, J. R. APC selectively mediates response to chemotherapeutic agents in breast cancer BMC Cancer 2015, 15 (1) 457 10.1186/s12885-015-1456-x
41. Olive, P. L.; Durand, R. E. Drug and radiation resistance in spheroids: cell contact and kinetics Cancer Metastasis Rev. 1994, 13 (2) 121-138 10.1007/BF00689632
42. Kerbel, R. S.; St Croix, B.; Florenes, V. A.; Rak, J. Induction and reversal of cell adhesion-dependent multicellular drug resistance in solid breast tumors Hum Cell. 1996, 9 (4) 257-264
43. Fallahi-Sichani, M.; Honarnejad, S.; Heiser, L. M.; Gray, J. W.; Sorger, P. K. Metrics other than potency reveal systematic variation in responses to cancer drugs Nat. Chem. Biol. 2013, 9 (11) 708-714 10.1038/nchembio.1337
44. Ahmed, D.; Eide, P. W.; Eilertsen, I. A.; Danielsen, S. A.; Eknæs, M.; Hektoen, M.; Lind, G. E.; Lothe, R. A. Epigenetic and genetic features of 24 colon cancer cell lines Oncogenesis 2013, 2, e71 10.1038/oncsis.2013.35
45. Chow, A. K. M.; Cheng, N. S. M.; Lam, C. S. C.; Ng, L.; Wong, S. K.; Wan, T. M.; Man, J. H.; Cheung, A. H.; Yau, T. C.; Poon, J. T.; Law, W. L.; Pang, R. W. Preclinical analysis of the anti-tumor and anti-metastatic effects of Raf265 on colon cancer cells and CD26(+) cancer stem cells in colorectal carcinoma Mol. Cancer 2015, 14, 80 10.1186/s12943-015-0352-y
46. Oikonomou, E.; Makrodouli, E.; Evagelidou, M.; Joyce, T.; Probert, L.; Pintzas, A. BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells Neoplasia. 2009, 11 (11) 1116-1131 10.1593/neo.09514
47. McDermott, L.; Qin, C. Allosteric MEK1/2 inhibitors for the treatment of cancer: an overview J. drug Res. Dev. 2015, 1 (1) 1-9 10.16966/2470-1009.101
48. Yamaguchi, T.; Kakefuda, R.; Tajima, N.; Sowa, Y.; Sakai, T. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo Int. J. Oncol. 2011, 39 (1) 23-31 10.3892/ijo.2011.1015
49. Qiao, L.; Koutsos, M.; Tsai, L. L.; Kozoni, V.; Guzman, J.; Shiff, S. J.; Rigas, B. Staurosporine inhibits the proliferation, alters the cell cycle distribution and induces apoptosis in HT-29 human colon adenocarcinoma cells Cancer Lett. 1996, 107 (1) 83-89 10.1016/0304-3835(96)04346-7
50. Mueller, A.; Bachmann, E.; Linnig, M.; Khillimberger, K.; Schimanski, C. C.; Galle, P. R.; Moehler, M. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines Cancer Chemother. Pharmacol. 2012, 69 (6) 1601-1615 10.1007/s00280-012-1869-z
51. Harmalkar, M. N.; Shirsat, N. V. Staurosporine-induced growth inhibition of glioma cells is accompanied by altered expression of cyclins, CDKs and CDK inhibitors Neurochem. Res. 2006, 31 (5) 685-692 10.1007/s11064-006-9068-0
52. Lu, K. V.; Zhu, S.; Cvrljevic, A.; Huang, T. T.; Sarkaria, S.; Ahkavan, D.; Dang, J.; Dinca, E. B.; Plaisier, S. B.; Oderberg, I.; Lee, Y.; Chen, Z.; Caldwell, J. S.; Xie, Y.; Loo, J. A.; Seligson, D.; Chakravari, A.; Lee, F. Y.; Weinmann, R.; Cloughesy, T. F.; Nelson, S. F.; Bergers, G.; Graeber, T.; Furnari, F. B.; James, C. D.; Cavenee, W. K.; Johns, T. G.; Mischel, P. S. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients Cancer Res. 2009, 69 (17) 6889-6898 10.1158/0008-5472.CAN-09-0347
53. Cha, J. H.; Choi, Y. J.; Cha, S. H.; Choi, C. H.; Cho, W. H. Allicin inhibits cell growth and induces apoptosis in U87MG human glioblastoma cells through an ERK-dependent pathway Oncol. Rep. 2012, 28 (1) 41-48
54. Végran, F.; Boidot, R.; Oudin, C.; Defrain, C.; Rebucci, M.; Lizard-Nacol, S. Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer Oncogene 2007, 26 (2) 290-297 10.1038/sj.onc.1209784
55. Ham, S. L.; Nasrollahi, S.; Shah, K. N.; Soltisz, A.; Paruchuri, S.; Yun, Y. H.; Luker, G. D.; Bishayee, A.; Tavana, H. Phytochemicals potently inhibit migration of metastatic breast cancer cells Integr Biol. 2015, 7 (7) 792-800 10.1039/C5IB00121H
56. Arima, Y.; Hayashi, N.; Hayashi, H.; Sasaki, M.; Kai, K.; Sugihara, E.; Abe, E.; Yoshida, A.; Mikami, S.; Nakamura, S.; Saya, H. Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer Int. J. Cancer 2012, 130 (11) 2568-2579 10.1002/ijc.26271
57. Akashi-Tanaka, S.; Watanabe, C.; Takamaru, T.; Kuwayama, T.; Ikeda, M.; Ohyama, H.; Mori, M.; Yoshida, R.; Hashimoto, R.; Terumasa, S.; Enokido, K.; Hirota, Y.; Okuyama, H.; Nakamura, S. BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy Clin. Breast Cancer 2015, 15 (1) 80-85 10.1016/j.clbc.2014.08.003
58. Sprouse, A. A.; Herbert, B.-S. Resveratrol augments paclitaxel treatment in MDA-MB-231 and paclitaxel-resistant MDA-MB-231 breast cancer cells Anticancer Res. 2014, 34 (10) 5363-5374
59. Song, M. S.; Salmena, L.; Pandolfi, P. P. The functions and regulation of the PTEN tumour suppressor Nat. Rev. Mol. Cell Biol. 2012, 13 (5) 283-296 10.1038/nrm3330